Liquidia Corporation

NasdaqCM:LQDA Stock Report

Market Cap: US$1.1b

Liquidia Valuation

Is LQDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LQDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LQDA ($14.75) is trading below our estimate of fair value ($55.84)

Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LQDA?

Other financial metrics that can be useful for relative valuation.

LQDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue63.6x
Enterprise Value/EBITDA-15.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does LQDA's PB Ratio compare to its peers?

The above table shows the PB ratio for LQDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.1x
ANIP ANI Pharmaceuticals
3.1x37.4%US$1.4b
COLL Collegium Pharmaceutical
6.3x25.4%US$1.3b
OCUL Ocular Therapeutix
14.8x26.6%US$1.4b
HRMY Harmony Biosciences Holdings
4.1x25.8%US$1.9b
LQDA Liquidia
23.7x59.5%US$1.1b

Price-To-Book vs Peers: LQDA is expensive based on its Price-To-Book Ratio (23.7x) compared to the peer average (7.1x).


Price to Earnings Ratio vs Industry

How does LQDA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: LQDA is expensive based on its Price-To-Book Ratio (23.7x) compared to the US Pharmaceuticals industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is LQDA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LQDA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio23.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LQDA's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LQDA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.75
US$23.86
+61.7%
38.8%US$32.00US$3.00n/a7
Mar ’25US$14.52
US$21.14
+45.6%
42.9%US$30.00US$3.00n/a7
Feb ’25US$13.60
US$20.86
+53.4%
44.2%US$30.00US$3.00n/a7
Jan ’25US$12.03
US$18.29
+52.0%
46.4%US$30.00US$3.00n/a7
Dec ’24US$7.27
US$14.00
+92.6%
34.1%US$18.00US$3.00n/a7
Nov ’24US$6.59
US$14.00
+112.4%
34.1%US$18.00US$3.00n/a7
Oct ’24US$6.34
US$14.00
+120.8%
34.1%US$18.00US$3.00n/a7
Sep ’24US$7.00
US$14.00
+100.0%
34.1%US$18.00US$3.00n/a7
Aug ’24US$7.80
US$14.00
+79.5%
34.1%US$18.00US$3.00n/a7
Jul ’24US$7.85
US$14.29
+82.0%
35.4%US$20.00US$3.00n/a7
Jun ’24US$8.63
US$14.29
+65.5%
35.4%US$20.00US$3.00n/a7
May ’24US$6.68
US$14.29
+113.9%
35.4%US$20.00US$3.00n/a7
Apr ’24US$6.91
US$14.29
+106.7%
35.4%US$20.00US$3.00n/a7
Mar ’24US$7.43
US$14.00
+88.4%
35.0%US$20.00US$3.00US$14.527
Feb ’24US$6.39
US$13.14
+105.7%
39.3%US$20.00US$3.00US$13.607
Jan ’24US$6.37
US$13.14
+106.3%
39.3%US$20.00US$3.00US$12.037
Dec ’23US$5.31
US$13.14
+147.5%
39.3%US$20.00US$3.00US$7.277
Nov ’23US$5.18
US$13.29
+156.5%
38.1%US$20.00US$3.00US$6.597
Oct ’23US$5.44
US$13.29
+144.2%
38.1%US$20.00US$3.00US$6.347
Sep ’23US$4.86
US$13.29
+173.4%
38.1%US$20.00US$3.00US$7.007
Aug ’23US$4.97
US$12.86
+158.7%
31.0%US$17.00US$4.00US$7.807
Jul ’23US$4.24
US$11.83
+179.1%
31.8%US$16.00US$4.00US$7.856
Jun ’23US$3.89
US$11.83
+204.2%
31.8%US$16.00US$4.00US$8.636
May ’23US$5.44
US$11.75
+116.0%
30.9%US$16.00US$6.00US$6.684
Apr ’23US$7.14
US$11.75
+64.6%
30.9%US$16.00US$6.00US$6.914
Mar ’23US$6.50
US$10.25
+57.7%
39.3%US$16.00US$6.00US$7.434

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.